Key Takeaways
- India base business accelerates, Semaglutide steals the show: Base business grew 16% ex-JB, outpacing the IPM, while the Semaglutide launch captured a 38% generic market share and is tracking toward a ₹200-250 cr first year, far exceeding prior blockbuster launches.
- JB Pharma integration running ahead of plan: Cost synergy extraction is tracking earlier than the original ~20% year-1 phasing, and JB’s attrition rate has already been pulled below the industry average, though revenue synergies remain a future story.
- Brazil is the next growth engine, but the Semaglutide play is a bet on Wegovy: Double-digit growth is expected, driven by new launches in large markets, yet Torrent has filed for the declining Ozempic and not yet for the fast-growing Wegovy, creating a timing risk.
- Margins on the blockbuster are a deliberate trade-off: Semaglutide’s EBITDA margin is much lower at launch due to high API costs and elevated spending, with management prioritizing market share over near-term profitability and expecting a reversal next year.
- What to watch next quarter: Whether oral Semaglutide API costs fall as forecast and margins begin to inflect, the pace of JB synergy realization against the accelerated timeline, and any update on the Wegovy filing in Brazil.
India Business & the Semaglutide Opportunity
- Base business momentum: The ex-JB India business grew 15% against an IPM growth of 10%, making Torrent one of the fastest-growing top-10 companies on a full-year basis, with Curatio growing 27% in FY26 driven by OTC ad spends and field force expansion.
- Semaglutide launch dominance: Torrent held a 38% share among generic players per April PharmaTrac data, with 28% share in the injectable format and 100% share in the oral format, supported by a two-month head start that management believes will sustain a majority market share even as new oral competitors enter.
- Oral pricing reset: Torrent reduced the oral Semaglutide price to ₹109 per tablet from ₹149, and management stated no further reduction is planned from here, anchoring the competitive landscape.
- Profitability deferred by design: The Semaglutide franchise carries much lower EBITDA margins at launch because of higher API prices and elevated spending, with the injectable sourced from a partner and the oral API outsourced, though oral API prices are dropping significantly and margins should reach a reasonably high level in the next 6 to 12 months.
- Market size ambition: The previous high-market-share launch, Sitagliptin in 2023, did ₹70-75 cr in its first year, while Semaglutide may reach ₹200-250 cr at this stage, a step-change in launch scale for Torrent.
Aman Mehta: "our approach has anyway been to look at market share first and profitability later, and hopefully by next year I think it should start reversing."
JB Pharma Integration & Synergies
- Cost synergies arriving early: The synergy plan for the first year is tracking ahead of expectations, with some costs taken out sooner than originally planned, and management acknowledged that what was expected next year may be delivered this year, though it deferred quantifying whether the full-year FY27 number will exceed the original 20% target.
- Revenue synergies still on the come: Confidence in revenue synergies is getting higher, but the timeline remains unchanged and no material revenue synergies are expected this year.
- Attrition normalized rapidly: JB’s attrition, which was higher than the industry average pre-acquisition, came down to below the industry average in April, though it still has a long way to go to reach Torrent’s base business attrition in the high single digits.
- MR force at scale: With the combined Torrent and JB representative strength, management sees no need to add further MRs, and the plan is to expand Torrent’s own count to 7,500 in FY27 before freezing expansion once JB’s MR strength is merged.
- Merger nearing completion: The NCLT final hearing for the JB Pharma merger is scheduled for next month, marking the last stage of the process after shareholder approval was received.
Aman Mehta: "What was expected next year may be delivered this year. Next year whether the actual synergy number is higher or not, that we can share maybe in a couple of more quarters."
Brazil: Growth Engine with a Semaglutide Timing Gap
- Broad-based growth drivers: Brazil delivered healthy volume growth with mid-single-digit price increases, and new launches in large markets like Rosuvastatin and Ezetimibe are getting good traction, alongside the first oncology product launch.
- Double-digit trajectory: Management expects 10% to 15% top-line growth in Brazil over FY26-27, with new introductions remaining the main driving force in the business.
- The Ozempic-to-Wegovy shift: Torrent’s Ozempic file is under review and the company expects to be among the first five players on the Ozempic side, but the Ozempic market is declining rapidly as patients transfer to Wegovy, and Torrent has not yet filed Wegovy in Brazil, though it is working toward it.
- Regulatory enforcement tightening: Since Wegovy’s launch in Brazil about a year ago, ANVISA has become very strict and substitution between the two products is no longer possible, making the Wegovy filing decision material to Torrent’s ability to capture the growing portion of the market.
Sanjay Gupta: "Ozempic is going declining very fast and Wegovy is growing very fast... all the companies so far that have filed have filed Ozempic. There have been no filers of Wegovy."
International Markets: Mixed Trajectories
- Germany disrupted by supplier issues: Growth was impacted by disruption at a third-party supplier, with constant-currency revenue down 1%, and management guided to low single-digit growth below 5% in constant currency for the next year.
- Biosimilar entry as a new vector: Torrent launched its first biosimilar in Germany, and the European biosimilar landscape changed in April when products were made substitutable with procurement moving through tenders, the channel Torrent operates in, with the first tenders expected in the June-July timeframe.
- US steady but unspectacular: Growth came from new launches achieving target market share and increased purchase volume on existing products, with a single-digit number of launches planned over the coming 9-10 months and single-digit growth expected for the next couple of years before a major product launch, with no 180-day exclusivity products where Torrent is the sole Day 1 filer.
- JB Pharma international CDMO drag: The international CDMO business was impacted by the change of control, realignment of business practices, and the ongoing geopolitical situation in the Middle East.
Pipeline & R&D Allocation
- Resmetirom for NASH: Torrent is conducting a Phase 3 clinical trial for Resmetirom, a USFDA-approved NASH therapy with no innovator present in India, and expects to launch within 12 to 18 months after patent expiry within the next year, with the objective that any such new launch should add a minimum of 1% to 2% to total India growth over the first year or two.
- First-to-market Brexpiprazole: Torrent was first to launch generic Brexpiprazole in India in April after conducting clinical trials.
- R&D spend reallocation: No material increase in total R&D spend is expected, with an incremental 0.5% anticipated in the upcoming year largely directed to India and the US, funded by reallocating spends from other markets.
- China in-licensing in progress: Torrent is in talks with multiple companies for oncology products in China, with deal terms being worked out.
Aman Mehta: "Our objective is that any new such launch should add incrementally minimum 1% to 2% to the total India growth over the first year or two years of launch."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India organic growth | Mid-teens growth realistic | FY27, absent external demand shocks |
| Semaglutide oral margins | Reach reasonably high level as API prices drop | Next 6 to 12 months |
| Semaglutide franchise profitability | EBITDA margin should start reversing | By next year (FY27) |
| Brazil top-line growth | 10% to 15% | FY26-27 |
| Germany constant-currency growth | Low single-digit, below 5% | Next year |
| US growth | Single-digit | Next couple of years, before major product launch |
| JB Pharma cost synergies | Up to INR 450 crores total, ~20% in year 1, phasing potentially earlier | By year 3; year 1 tracking ahead |
| JB Pharma revenue synergies | No material contribution | This year |
| Resmetirom (NASH) launch | Within 12 to 18 months, after patent expiry | Patent expires within next year |
| India MR count | Expand Torrent to 7,500, then freeze post-JB merger | FY27 |
| Oral Semaglutide pricing | No further reduction from ₹109 per tablet | Ongoing |
| Germany biosimilar tenders | Begin participating | June-July timeframe |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹4,197 cr, up 42% YoY |
| Operating EBITDA | ₹1,356 cr, up 41% YoY |
| Operating EBITDA margin | 32.3% (combined); 32.7% ex-JB |
| India business revenue | ₹2,215 cr, up 43% YoY (includes JB); base business ex-JB up 15% vs IPM growth of 10% |
| Brazil constant currency revenue | BRL 25.9 cr, up 11% YoY; IQVIA growth 17% vs market 6% |
| US constant currency revenue | USD 3.8 cr, up 9% YoY |
| Germany constant currency revenue | EUR 3.1 cr, down 1% YoY |
| Full-year overall revenue growth | 15% (FY26) |
| Full-year operating EBITDA margin | 32.7% (FY26) |
| Net debt to EBITDA | 2.3x, considering JB's full-year FY26 EBITDA |
| Final dividend | ₹9 per equity share |
| India field force | 7,100 ex-JB at year-end; plan to reach 7,500 in FY27 |
| Semaglutide generic market share | 38% overall, 28% injectable, 100% oral (PharmaTrac April data) |
| Semaglutide April sales | ~₹17 cr total (both brands, all formats); oral ₹6 cr, injectable ₹11 cr |
| Curatio business growth | 27% in FY26 |
| Brazil volume growth | Flat to slightly negative in Q4 |
| Brazil price increase | 5% in Q4 |
| Brazil new introductions contribution | ~7% in Q4 |
| Brazil molecules awaiting ANVISA approval | 58 |
| R&D spend | ~5% of sales in FY26; incremental 0.5% expected in FY27 |
| Cost synergy guidance (JB Pharma) | Up to ₹450 cr by year 3; ~20% in year 1 |
| Torrent base business attrition | High single-digit |
| India base business PharmaTrac growth breakup | 3.8% volume, 6.7% price, 3.4% new products (vs market 1.7%, 5.5%, 3.3%) |
| Semaglutide internal sales projection | ₹200 cr to ₹250 cr at this stage |
| Oral Semaglutide price | ₹109 per tablet, reduced from ₹149 |
| Amortization charge (JB acquisition) | ₹257 cr; net negative after deferred tax reversal of ~₹62-63 cr is minus ₹195 cr |
| JB PAT for stub period | ₹143 cr |
| Exceptional items | ₹46 cr (Torrent), ₹19 cr (JB), both in Q4 |